In attention deficit hyperactivity disorder (ADHD), doctors are "starving for something new, something refreshing, something that can really add value and is not only a formulation of an existing amphetamine or methylphenidate," said Supernus Pharmaceuticals Inc. CEO Jack Khattar – and in fast-onset SPN-812, they just might have it.